<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941901</url>
  </required_header>
  <id_info>
    <org_study_id>AA1232</org_study_id>
    <nct_id>NCT01941901</nct_id>
  </id_info>
  <brief_title>Calcium Electroporation for Treatment of Cutaneous Metastases</brief_title>
  <official_title>Calcium Electroporation for Treatment of Cutaneous Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of calcium electroporation on cutaneous
      metastases, and compare calcium electroporation with standard treatment: electrochemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blinded phase II clinical study. We will compare the effect of calcium electroporation
      for the treatment of cutaneous metastases with standard treatment: electrochemotherapy with
      intratumoral injection of bleomycin. Separate randomisation will be performed and the lesions
      will be treated with either intratumoral injection of calcium or bleomycin. It is a once only
      treatment and the patients will be followed up for 6 months.

      It is a non-inferiority study and we accept a difference in response on 15%.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>After 6 months</time_frame>
    <description>Response evaluated by &quot;Response Evaluation Criteria in Solid Tumors&quot; (RECIST) guidelines version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events to calcium electroporation</measure>
    <time_frame>After 6 months</time_frame>
    <description>Describe adverse events using Common Terminology for Adverse Events, version 4.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Compare tumor response of calcium electroporation with tumor response of electroporation. Response is evaluated by RECIST criteria.</measure>
    <time_frame>After 6 months</time_frame>
    <description>It is a non-inferiority study, and we accept a difference in response on 15%.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Cutaneous Metastases</condition>
  <arm_group>
    <arm_group_label>Calcium electroporation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.
It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Electrochemotherapy with bleomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.
It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium electroporation</intervention_name>
    <description>Intratumoral injection, once only treatment.</description>
    <arm_group_label>Calcium electroporation</arm_group_label>
    <other_name>Calcium chloride.</other_name>
    <other_name>ATC code: A02AC</other_name>
    <other_name>EV substance code SUB12664MIG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Electrochemotherapy with bleomycin</intervention_name>
    <description>Intratumoral injection, once only treatment</description>
    <arm_group_label>Electrochemotherapy with bleomycin</arm_group_label>
    <other_name>ATC code L01DC01</other_name>
    <other_name>EV substance code SUB00844MIG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  Histological confirmed cutaneous metastases of any histology.

          -  At least 1. cutaneous metastases between 0,5 to 3cm, available to electroporation.

          -  Patient should have been offered standard treatment.

          -  At least 2 weeks since chemotherapy or radiotherapy.

          -  Performance status &gt;2 (ECOG).

          -  Life expectancy &gt;3 months.

          -  platelet count &gt; 50 mia/l.

          -  International Normalized Ratio (INR) &lt;1,2.

          -  Men and women of reproductive age must use effective contraception during the study.

          -  Patient should be able to understand participants information.

          -  Signed, informed consent.

        Exclusion Criteria:

          -  Previously treatment with bleomycin &gt; 200.000 Units/m2.

          -  Allergy to bleomycin.

          -  Clinically significant coagulopathy.

          -  Pregnancy or lactation.

          -  Participation in other clinical trial involving experimental drugs or participation in
             a clinical trial within 4 weeks before study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Gehl</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, Copenhagen University hospital, Herlev</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Gehl</last_name>
    <phone>004538683868</phone>
    <email>julie.gehl@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Oncology, Copenhagen University Hospital, Herlev</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Gehl</last_name>
      <phone>004538683868</phone>
      <email>julie.gehl@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Julie Gehl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>August 28, 2015</last_update_submitted>
  <last_update_submitted_qc>August 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Julie Gehl</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Cutaneous metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

